Get the Daily Brief
Latest Biotech News
Immuneering’s pancreatic pill posts survival edge – pivotal plans loom
Immuneering reported updated Phase 2a results for the MEK inhibitor atebimetinib combined with modified chemotherapy in first‑line pancreatic cancer, showing a 64% one‑year overall survival rate...
FDA cuts didn’t derail review clocks – staff kept drug timetables intact
An analysis found that despite extensive staff departures and leadership turnover at the FDA in 2025, reviewers largely met their user‑fee timelines for new drug reviews. Agency line staff...
Lilly buys Ventyx for $1.2B – bolsters oral NLRP3 pipeline
Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion to secure clinical-stage NLRP3 inhibitors and expand its inflammation and neurodegeneration portfolio. Lilly said the deal...
Parabilis raises $305M — pushes corkscrew peptides toward late‑stage testing
Parabilis Medicines closed a $305 million Series F to advance its Helicon peptide platform and lead candidate zolucatetide into later‑stage testing for oncology. The round, led by RA Capital,...
EpiBiologics nets $107M — prepares EPI‑326 for first‑in‑human studies
EpiBiologics announced a $107 million Series B to advance its extracellular protein degradation platform and its lead bispecific degrader, EPI‑326, toward clinical testing. The round was led by GV...
Alumis’ TYK2 pill tops Phase III — envudeucitinib stakes psoriasis claim
Alumis reported positive Phase III Onward1 and Onward2 results for its oral TYK2 inhibitor envudeucitinib in psoriasis, data that position the pill among leading oral therapies for the disease....
Immuneering’s pancreatic pill posts 64% one‑year survival — pivotal next
Immuneering reported updated Phase 2a data showing a 64% overall survival rate at 12 months for atebimetinib combined with modified chemotherapy in first‑line pancreatic cancer—well above...
GSK and Ionis claim Phase III wins for bepirovirsen — filings planned
GSK and partner Ionis announced positive topline results from two pivotal Phase III trials (B‑Well 1 and B‑Well 2) of bepirovirsen, an antisense oligonucleotide designed to deliver a functional...
GSK licenses Noetik’s cancer foundation models — $50M upfront
GSK paid $50 million upfront to license Noetik’s foundation AI models for colorectal and non‑small‑cell lung cancer, moving from bespoke AI services to a subscription licensing framework. The...
Guardant’s Shield wins Tricare coverage — military members gain copay‑free CRC blood test
Guardant Health said Tricare will cover its Shield blood‑based colorectal cancer screening test with no copay for eligible active‑duty service members and dependents aged 45 and older at average...
Diagonal raises $125M — clustering antibodies head to first‑in‑human
Diagonal Therapeutics closed a $125 million Series B co‑led by Sanofi Ventures to advance DIAG723—its clustering antibody designed for hereditary hemorrhagic telangiectasia (HHT) and pulmonary...
Vizgen raises $48M — scales MERFISH spatial biology and commercial push
Vizgen closed a $48 million financing led by Arch Venture Partners, M Ventures and Northpond Ventures to accelerate commercial growth, scale operations and push toward profitability. The company...
Lilly buys Ventyx for $1.2B – Acquires NLRP3 oral drugs
Eli Lilly agreed to acquire Ventyx Biosciences for about $1.2 billion in cash, securing clinical-stage NLRP3 inhibitors that Lilly says expand its inflammation franchise. The deal values Ventyx at...
Parabilis raises $305M: Push to advance corkscrew peptides into late-stage cancer testing
Parabilis Medicines closed a $305 million Series F to accelerate development of its corkscrew-shaped peptide therapeutics, funding late-stage advancement of its lead oncology candidate. The...
EpiBiologics nets $107M – Funds first-in-human protein-degrading antibody
EpiBiologics closed a $107 million Series B to advance its EpiTAC protein-degrading antibody platform into human testing, with GV and Johnson & Johnson’s venture arm leading the round. The Bay...
Alumis’ TYK2 pill clears Phase III – Psoriasis efficacy intensifies competition
Alumis reported positive top-line results from two Phase III trials of envudeucitinib, a selective oral TYK2 inhibitor, meeting co-primary endpoints for skin clearance in moderate-to-severe plaque...
GSK, Ionis claim Phase 3 win: Bepirovirsen meets functional cure endpoints
GSK and Ionis announced positive results from two pivotal Phase 3 trials of bepirovirsen, an antisense oligonucleotide for chronic hepatitis B, reporting functional cure rates that met primary...
Spatial biology... Vizgen raises $48M; Singleron expands ANZ distribution
Vizgen closed a $48 million financing round led by Arch Venture Partners, M Ventures and Northpond Ventures to scale commercial operations for its spatial transcriptomics platform, expand...
Pfizer taps Gordian’s in vivo mosaic screens: Target discovery inside visceral fat
Pfizer and Gordian Bio struck a collaboration to apply Gordian’s in vivo mosaic screening platform to prioritize obesity targets directly within visceral adipose tissue. Gordian will run...
Sanofi inks up-to-$2.56B Earendil pact – AI to discover bispecifics
Sanofi signed a discovery and option collaboration with AI-driven Earendil Labs valued at up to $2.56 billion to use Earendil’s platform to identify bispecific antibody candidates for autoimmune...